AN2 Therapeutics grants inducement equity to new CMO
AN2 Therapeutics granted stock options for 233,333 shares at $5.36 and 116,667 RSUs to newly appointed CMO Cameron Trenor, M.D., vesting over four years under Nasdaq Rule 5635(c)(4).
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.